Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Resurrects Park Doctrine in Enforcement of Pharmaceutical GMPs

This article was originally published in The Gold Sheet

Executive Summary

FDA is following through on earlier threats to dust off the long-dormant Park doctrine for holding chief executive officers of pharmaceutical companies personally accountable for manufacturing problems.
Advertisement

Related Content

CDER Pharmaceutical Quality Office Gains Permanent Director
KV Official Is Excluded From Government Programs, The First Under OIG's New Guidance
J&J Faces Possible Criminal Liability As Post-Recall Overhaul Continues
Enforcement on Steroids: FDA Delivers Twice the Drug GMP Warning Letters
Enforcement on Steroids: FDA Delivers Twice the Drug GMP Warning Letters
Drug Recall Totals for 2008 Highlight Global Outsourcing and Other Risks
Advertisement
UsernamePublicRestriction

Register

PS000590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel